New drug combo tested in real patients for tough stomach cancers
NCT ID NCT07427992
Summary
This study is observing how well a new targeted drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. It aims to confirm the drug's effectiveness and safety in real-world patients, not just in controlled trials. The study will include about 70 adults whose cancer tests positive for a specific protein called Claudin 18.2 and is HER2-negative.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
European Institute of Oncology
RECRUITINGMilan, 20141, Italy
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.